ADC Therapeutics has dosed the first subject in the LOTIS-7 Phase Ib clinical trial of Zynlonta (loncastuximab tesirine-lpyl) along with other anti-cancer agents to treat relapsed or refractory B-cell non-Hodgkin lymphoma.
A CD19-directed antibody drug conjugate (ADC), Zynlonta is internalised by the cell once bound to a CD19-expressing cell.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Zynlonta received the US Food and Drug Administration (FDA) approval to treat relapsed or refractory large B-cell lymphoma in adult patients who have received two or more lines of systemic therapy.
The multi-centre, open-label, multi-arm LOTIS-7 Phase Ib clinical trial will include multiple arms in two parts, which include a dose escalation part, and a dose expansion part.
The first arm of the study will assess the activity and safety of Zynlonta along with polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma patients.
It will also assess the therapy in patients with mantle cell lymphoma, high grade B-cell lymphoma, Burkitt lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, and marginal zone lymphoma.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataADC Therapeutics chief medical officer Joseph Camardo said: “As Zynlonta has been shown in preclinical studies to have synergistic or additive effects when combined with other anti-cancer therapies, we are eager to explore the potential of our differentiated CD19-directed ADC in combination with other established therapies.
“We are excited by the opportunity to allow more lymphoma patients to achieve a response and benefit from the new combinations we are evaluating in LOTIS-7.”
In the LOTIS clinical trial programme, Zynlonta is also being assessed as a therapeutic option along with studies in other B-cell malignancies and earlier lines of therapy, said the company.
